Dr. Mihail Zilbermint
Dr. Mihail Zilbermint is a prominent medical expert affiliated with Johns Hopkins University, known for his insights into obesity treatments and pharmaceuticals. He recently commented on the competitive landscape of weight loss medications, particularly highlighting the differences between Eli Lilly's orforglipron and Novo Nordisk's offerings, emphasizing the importance of factors like production cost and usability in determining market success.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Slovenia | 1 | 7.00 | 0.09% | +0% | 2,078,938 | 1,794 | $56,000 | 48$ |
| Totals | 1 | 2,078,938 | 1,794 | $56,000 | 48$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Slovenia:
Dr. Mihail Zilbermint emphasized that both medications could change the game.
7